Immunotherapy for metastatic renal cell carcinoma

被引：22
作者：
McDermott, David F.
Rini, Brian I.
机构：
[1] Taussig Canc Ctr, Cleveland Clin, Dept Solid Tumor Oncol & Urol, Cleveland, OH 44195 USA
[2] Beth Israel Deaconess Med Ctr, DF HCC Renal Canc Program, Boston, MA 02215 USA
来源：
BJU INTERNATIONAL | 2007年 / 99卷 / 05期
关键词：
cytokine; renal cell carcinoma; interleukin-2; interferon;
D O I：
10.1111/j.1464-410X.2007.06818.x
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1282 / 1288
页数：7
相关论文
共 43 条
[1]   Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer [J].
Atkins, M ;
Regan, M ;
McDermott, D ;
Mier, J ;
Stanbridge, E ;
Youmans, A ;
Febbo, P ;
Upton, M ;
Lechpammer, M ;
Signoretti, S .
CLINICAL CANCER RESEARCH, 2005, 11 (10) :3714-3721
[2]  
Avigan David, 2003, Clin Breast Cancer, V3 Suppl 4, pS158, DOI 10.3816/CBC.2003.s.006
[3]  
Bui MHT, 2003, CLIN CANCER RES, V9, P802
[4]   Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation [J].
Childs, R ;
Chernoff, A ;
Contentin, N ;
Bahceci, E ;
Schrump, D ;
Leitman, S ;
Read, EJ ;
Tisdale, J ;
Dunbar, C ;
Linehan, WM ;
Young, NS ;
Barrett, AJ ;
Clave, E ;
Epperson, D ;
Mayo, V .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (11) :750-758
[5]   Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial [J].
Clark, JI ;
Atkins, MB ;
Urba, WJ ;
Creech, S ;
Figlin, RA ;
Dutcher, JP ;
Flaherty, L ;
Sosman, JA ;
Logan, TF ;
White, R ;
Weiss, GR ;
Redman, BG ;
Tretter, CPG ;
McDermott, D ;
Smith, JW ;
Gordon, MS ;
Margolin, KA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) :3133-3140
[6]   RETRACTED: Immunotherapy for advanced renal cell cancer - art. no. CD001425.pub2 (Retracted Article) [J].
Coppin, C ;
Porzsolt, F ;
Awa, A ;
Kumpf, J ;
Coldman, A ;
Wilt, T .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (01)
[7]   Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells [J].
Dannull, J ;
Su, Z ;
Rizzieri, D ;
Yang, BK ;
Coleman, D ;
Yancey, D ;
Zhang, AJ ;
Dahm, P ;
Chao, N ;
Gilboa, E ;
Vieweg, J .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (12) :3623-3633
[8]  
Fisher RI, 2000, CANCER J SCI AM, V6, pS55
[9]   RESULTS OF TREATMENT OF 255 PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA WHO RECEIVED HIGH-DOSE RECOMBINANT INTERLEUKIN-2 THERAPY [J].
FYFE, G ;
FISHER, RI ;
ROSENBERG, SA ;
SZNOL, M ;
PARKINSON, DR ;
LOUIE, AC .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :688-696
[10]  
Golgher D, 2002, EUR J IMMUNOL, V32, P3267, DOI 10.1002/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO
12345